The phrase "advanced to a phase" is correct and usable in written English.
It can be used when describing progress or development in a process, project, or situation.
Example: "After several months of research, the project has advanced to a phase where we can begin testing the prototype."
Alternatives: "moved to a stage" or "progressed to a level".
Phase II studies traditionally are designed to establish efficacy of an experimental regimen before advancing to a phase III study.
Iran Claims Breakthrough In Ability to Enrich Uranium Iran announced that its nuclear engineers had advanced to a new phase in the enrichment of uranium, and President Mahmoud Ahmadinejad and the country's ruling clerics declared that the nation would now speed ahead, in defiance of a United Nations resolution, to produce the nuclear fuel on an industrial scale.
TEHRAN, April 11 — Iran announced Tuesday that its nuclear engineers had advanced to a new phase in the enrichment of uranium, and President Mahmoud Ahmadinejad and a series of the country's ruling clerics declared that the nation would now speed ahead, in defiance of a United Nations Security Council warning, to produce nuclear fuel on an industrial scale.
However, only one 90Y-labelled radioimmunconjugate (90Y-muHMFG1) for the treatment of OC has advanced to a clinical phase III trial.
This is the first measurement of both length scales as the system is advanced to an unstable phase boundary by adding barium chloride salt.
The fact the trial is even advancing to such a phase — taking aim at congressmen, members of the governing party and senior officials who worked directly under one of the most popular presidents — points to a rare breakthrough in political accountability and a crucial streak of independence in the legal system.
This research has been mainly triggered and promoted by the development of potent HDAC inhibitors (HDI) that have already advanced to late phase clinical trials for a broad variety of malignant human neoplasms [ 10, 11].
With promising preclinical efficacy, MLN4924 has been advanced to several Phase I clinical trials against a number of human malignancies.
Fourteen compounds registered in Phase 2 were advanced to Phase 3 and tested during the decade reviewed (8% advance rate; 92% attrition rate).
